3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Renal Cell
29
Carcinoma, Hepatocellular
16
Prostatic Neoplasms
12
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Neoplasms
8
Sarcoma
7
Osteosarcoma
6
Neuroendocrine Tumors
6
Brain Neoplasms
6
Urinary Bladder Neoplasms
5
Kidney Neoplasms
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Sarcoma, Ewing
4
Melanoma
4
Lung Neoplasms
4
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoid Tumor
3
Adrenocortical Carcinoma
3
Adenocarcinoma
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Urethral Neoplasms
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Thyroid Cancer, Papillary
2
Interventions
pembrolizumab
3
apatinib
3
Magnetic Resonance Spectroscopy
3
lenvatinib
2
Specimen Handling
2
Nivolumab
2
Imatinib Mesylate
2
Epirubicin
2
Cisplatin
2
Carboplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
regorafenib
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
Tretinoin
1
Sunitinib
1
Radiation
1
Pemetrexed
1
Nelfinavir
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Glutamate Carboxypeptidase II
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Adenoid Cystic
×
cabozantinib
×
Clear all
NCT03729297
2021-03-12
Cabo ASAP
Radboud University Medical Center
Phase 2
Terminated
25 enrolled